Moderator's view: after SGLT2i and MRA antagonists, where do we go?
Moderator's view: after SGLT2i and MRA antagonists, where do we go?
About this item
Full title
Moderator's view: after SGLT2i and MRA antagonists, where do we go?
Author / Creator
Publisher
England: Oxford University Press
Journal title
Clinical kidney journal, 2024-02, Vol.17 (2), p.sfae013-sfae013
Language
English
Formats
Publication information
Publisher
England: Oxford University Press
Subjects
More information
Alternative Titles
Full title
Moderator's view: after SGLT2i and MRA antagonists, where do we go?
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2928588360
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2928588360
Other Identifiers
ISSN
2048-8505
E-ISSN
2048-8513
DOI
10.1093/ckj/sfae013
